Best Life Sciences Companies in Central District, Israel

BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson’s disease (PD). NurOwn is BrainStorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. Its platform technology essentially converts MSCs into living drug delivery systems for NTFS. They use animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury.

Funding rounds

• Feb 2026Post IPO$1M
• Jun 2020Grant (prize money)$500K
• Apr 2020Grant (prize money)$1.5M
• Nov 2019Grant (prize money)$495.3K

Founders & team

Chaim LebovitsChief Executive Officer

Investors

Portalsaude, Israel Innovation Authority, National MS Society, I AM ALS, ALS Association, Iconic Private Equity Partners

Tech stack

AstraCdnjsCloudflareCloudflare Bot ManagementCore-JsDraftpress Hfcm

PolyPid has developed a technology platform (PLEX-Polymer-Lipid Encapsulation matriX) that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). Its technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. It allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. Its pipeline includes D-PLEXantibiotic drug reservoir designed to be implanted during surgery to prevent or treat surgical site infections (SSIs)), Bonypid-1000 (an antibiotic designed for bone related infections applications) and Bonypid-500 (an antibiotic eluting bone graft substitute intended to fill, augment or reconstruct periodontal or oral/maxillofacial defects while protecting from infections)

VVT Medical has developed a medical technology for the treatment of varicose veins. Its procedure called V-Block includes a percutaneous delivery of vascular embolic device (called v-block device) into the proximal great saphenous vein (GSV) and induce a concomitant liquid sclerotherapy using its proprietary dual procedure syringe system by the simultaneous aspiration of the blood and the discharging of the sclerosing agent. Claims that the procedure requires no anesthesia and requires minimal post procedure care.

Biobeat offers a non-invasive body vitals monitoring wearable solution. It uses reflective Pulse Oximetry technology with their algorithm to allow for constant measurements of related body vitals. Sensor delivers a range of body vitals measurement including consciousness, saturation, pulse, temperature and perspiration. The devices are connected to a mobile app or a central monitoring system where the user's data is stored. Data is then compared against a person's normal levels to identify life-threatening situations. It also allows data sharing with doctors and caregivers. They have released their products for athletes and Hospitals. Founded by Arik Ben Ishai Director of startups in the Rocket and Space Department of the Ministry of Defense, Israel.

Provider of AI-powered bioprocess optimization solutions. It uses hybrid models, digital twins, and advanced AI technologies to accelerate bioprocess development and scale-up. The platform allows users to upload data, calibrate models, and create digital twins for gaining insights into cell line metabolism, optimizing protocols, and ensuring seamless transitions from pilot to manufacturing. This approach reduces trial-and-error experimentation, improves cell productivity, and enables real-time optimization during production. Key technologies include engineering models, data intelligence, design of experiments, AI optimization algorithms, and hybrid biological models.

Funding rounds

• Jul 2025Seed$2.8M
• Jul 2025Grant (prize money)—

Founders & team

Omri SchaninCo-Founder & CEOEyal BetzalelCo-Founder & CTO

Investors

Good Company, Innovation Israel

Tech stack

Amazon Web ServicesCalendlyCloudflareCloudflare Bot ManagementCore-JsElementor

Developer of minimally invasive, bioelectronic solutions to treat spinal and synovial joint conditions. it offers minimally invasive, implantable device to treat and reverse degenerative disc disease by restoring the discs healthy fluid dynamics, cushioning and stability to the spine, revive disc cells, and accelerate tissue healing, to reduce pain and restore function.

Funding rounds

• Sep 2024Series A$11M
• Seed$5M

Founders & team

Yuval MandelbaumCEO

Investors

Supernova Invest, Sanara Capital, Bold Capital Partners

Developer of a medical device for treating respiratory failure. The company has an ART500 device based on augmented respiration technology which draws a liter of blood through a cannula, removes co2, and returns oxygenated blood to the circulatory system. This elevates the blood oxygen saturation levels and prevents respiratory failure.

Funding rounds

• Dec 2024Post IPO$8.3M

Founders & team

Joe HayonCo-Founder & President & CFODagi NoonCo-Founder & CEOUdi NussinovitchCo-Founder & Chief Scientific Officer

Tech stack

Amazon AlbAmazon Web ServicesCdnjsCloudflareCloudflare Bot ManagementCloudflare Browser Insights

Manufacturer of endovascular suture-like device for cardiovascular treatment. It uses a smart stapling mechanism that enables multiple staples to simultaneously penetrate the stent graft and the aortic wall. With a small profile delivery system, the device, Aortoseal is quickly deployed via a single release action. It enables the implementation of endograft procedures in almost all types of anatomies and can dramatically reduce complications and reinterventions.

Funding rounds

• Jul 2024Series A$10M
• Feb 2023Grant (prize money)$2.7M
• 2022Grant (prize money)$2.8M
• Dec 2021Seed$5M

Founders & team

Ron KarmeliCo-Founder & CMO

Investors

Sofinnova Partners, EIC Fund, MD Start, MedTech Innovator

Developer of an AI-based chip for genetic and epigenetic profiling. It offers a set of biomarkers that assists with the identification of different kinds of cancer. It has features for diagnostic tests with a multi-cancer approach system. The chip can be used for detecting genetic and epigenetic profiles

Funding rounds

• Jul 2024Grant (prize money)$2.7M
• Jan 2023Grant (prize money)$9.1M
• Jan 2023Grant (prize money)$1.9M
• 2022Seed$6M

Founders & team

Dror FeldheimCo-FounderJoel ElCo-FounderShahar ZirkinCo-Founder

Investors

Europa

CathWorks is developing FFRAngio, a novel technology for angiogram-based physiology measurement that does not require pressure wires or hyperemic stimulus. It is based on the processing of visual information and automatic multi-layered algorithms. Its technology is focused on improving the utilization of coronary angiography data to validate measurement-based medicine in the cath lab.

Funding rounds

• Jul 2022Series E$75M
• Jan 2021Series D$30M
• Feb 2019Series C$30M
• Oct 2017Series B$15.8M

Founders & team

Ifat LaviFounder & CTO

Investors

Medtronic, Deerfield, Quark Venture, Planven Investments, Pontifax, Corundum Open Innovation

Tech stack

Animate.CssCloudflareCloudflare Bot ManagementComplianzCore-JsGodaddy

AI-powered grain optimization for smarter milling and enhanced food production. They are revolutionizing the food industry by developing and optimizing grain crops using cutting-edge AI technology. Their Manna™ AI software empowers millers, traders, and ingredient processors to make informed decisions, improve purchasing power, enhance storage efficiency, and boost processing output. This SaaS platform analyzes grain properties, predicts performance, and provides actionable insights to save money, predict quality, boost operational efficiency, and reduce risk. They also breed innovative non-GMO crop varieties to meet specific food industry needs, driving food innovation from plant to plate. Their solutions optimize protein-crop processing and wheat baking quality, shaping the grain value chain with data-driven insights and precision.

Funding rounds

• Dec 2022Series D$35M
• Jun 2021Series C$20M
• Jan 2020Grant (prize money)$160.8K
• Dec 2019Series B$10M

Founders & team

Gil ShalevFounder & CEO

Investors

Europa, Fnx, Fortissimo Capital, BASF Venture Capital, The Trendlines Group, Maverick Ventures

Developer non-invasive molecular cancer diagnostic tests. The company uses DNA methylation patterns (epigenetics) to detect cancer using proprietary biomarker assays. Its first product, the Bladder EpiCheck is used to diagnose bladder cancer. In addition, the company has developed diagnostic tests for colorectal cancer and lung cancer.